TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published in Nature Medicine links lower NRF2 activity in oligodendrocytes—cells that maintain the brain’s myelin coating—to abnormal myelin, loss of large nerve fibers and faster cognitive decline. Mouse experiments support a possible role for NRF2, but the findings do not show that an existing drug can prevent age-related decline in people.
Researchers studying older adults and mice found that reduced NRF2 activity in oligodendrocytes—cells that maintain the protective myelin coating around nerve fibers—was linked to myelin abnormalities, nerve-fiber loss and faster cognitive decline. Published in Nature Medicine, the study points to a possible biological pathway for future research, but does not establish that a drug targeting it can prevent cognitive decline in people.
The team, led by researchers from the University of Edinburgh and the UK Dementia Research Institute, examined data from the Lothian Birth Cohort 1936. Participants had cognitive abilities recorded from childhood and were assessed between ages 70 and 82 for memory, processing speed and spatial reasoning. Of 1,091 people enrolled, 866 completed additional cognitive testing after age 70. The source report says nearly all experienced some decline, though the pace varied.
Researchers then examined brain tissue collected after death from a subset of participants. Greater decline over time was associated with fewer large nerve fibers and an abnormal buildup of myelin. The association concerned the rate of change in cognitive abilities, rather than performance at one particular age. The human tissue findings show a relationship; by themselves, they do not establish what caused it.
The researchers also found lower levels of NRF2, a protein involved in cellular defenses, in oligodendrocytes from people with more severe decline. In mice, reducing NRF2 specifically in these cells led to excessive myelin, loss of large nerve fibers and less improvement on cognitive tests as the animals aged. These experiments support a possible causal role for NRF2 loss in mice, but they cannot show that the same process drives decline in humans.
A Possible Target in Aging Brain Cells
The findings add a potential mechanism to research on age-related cognitive decline: cells that usually support nerve signaling may become less effective at maintaining myelin as the brain ages. Abnormal myelin and damage to large nerve fibers could interfere with how efficiently signals travel, offering researchers a route to investigate why some people decline faster than others.
The study also raises the possibility of targeting the NRF2 pathway. The source report notes that drugs acting on this pathway are used for other neurological conditions, including multiple sclerosis. That makes the pathway relevant to further drug research, not an established treatment for age-related decline. Testing would be needed to determine whether changing NRF2 activity is safe and beneficial for older adults, and whether any effects extend beyond the mouse findings.
From Cohort Records to Mouse Tests
The Lothian Birth Cohort gave researchers an unusual opportunity to compare later-life brain tissue with cognitive records extending back to childhood. Repeated assessments between ages 70 and 82 allowed the team to examine change over time, rather than relying only on a single test in old age. Brain tissue was available only for a subset of participants, so the human findings are based on that group, not all 1,091 enrollees.
Oligodendrocytes produce and maintain myelin, the insulating layer around nerve fibers that helps electrical signals travel. They have generally been studied for this supportive role. The research reframes them as cells whose age-related dysfunction may also contribute to damage. The mouse experiments tested that idea by reducing NRF2 in oligodendrocytes, while the human analysis identified associations in tissue and cognitive records.
The researchers identified a treatment possibility because the NRF2 pathway is already addressed by medicines prescribed for other conditions. The source report says prior studies found that increasing NRF2 activity can improve cognitive function in people with multiple sclerosis. That evidence concerns a different disease and does not establish a benefit for aging-related cognitive decline.
““As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.””
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
Human Treatment Evidence Is Missing
The study does not establish that low NRF2 activity causes cognitive decline in people. Its human findings come from associations between cognitive trajectories and postmortem tissue; the experiments that altered NRF2 were conducted in mice. It is also unclear how the observed cellular changes relate to particular causes of cognitive decline or whether they apply equally across older adults.
No evidence in the source report shows that an NRF2-targeting medicine prevents or slows age-related decline in people. The report does not specify which medicine might be tested, what dose would be appropriate, or what risks and benefits treatment could carry for older adults. Those questions require direct clinical research.
Testing the Pathway in People
The next step is to establish whether the findings can be reproduced and to clarify how NRF2 activity changes in human oligodendrocytes during aging. Researchers would then need to test candidate medicines in studies designed for age-related cognitive decline, measuring both safety and cognitive outcomes. Evidence from treatment of multiple sclerosis cannot substitute for those trials.
Until that work is done, the study offers a research direction rather than a new care option. The immediate development is a proposed link between a protective brain cell’s dysfunction and decline—not proof that restoring NRF2 will preserve memory or thinking abilities.
Key Questions
What brain cells did the study examine?
It focused on oligodendrocytes, cells that produce and maintain myelin, the coating around nerve fibers.
What did researchers find in people?
In postmortem tissue from a subset of the Lothian Birth Cohort, greater cognitive decline over time was associated with lower NRF2 levels in oligodendrocytes, fewer large nerve fibers and abnormal myelin buildup. These are associations, not proof of cause.
Does this study show that a drug can prevent cognitive decline?
No. The study identifies the NRF2 pathway as a possible target, but it does not report a clinical trial showing that an NRF2-targeting drug prevents or slows age-related decline in people.
Why were mice included in the research?
Researchers reduced NRF2 in oligodendrocytes in mice to test whether this change could produce brain abnormalities. The animals developed excess myelin, lost large nerve fibers and showed less improvement on cognitive tests as they aged; these results do not establish the same effect in humans.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
